Teva debuts 1% sodium hyaluronate
Teva is offering 1% sodium hyaluronate. The product is indicated for the treatment of pain in osteoarthritis, or OA, of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
“The launch of 1% sodium hyaluronate is a great example of using the expertise within Teva to bring together skills from both our generic and specialty business,” said Brendan O’Grady, executive vice president and head of North America commercial. “We are proud to bring an additional offering to the physicians and patients seeking treatment options for OA knee pain.”
Teva's 1% sodium hyaluronate is supplied in a 3 mL disposable prefilled syringe containing 2 mL of 1% sodium hyaluronate, and packaged as three syringes to a carton.
“The launch of 1% sodium hyaluronate is a great example of using the expertise within Teva to bring together skills from both our generic and specialty business,” said Brendan O’Grady, executive vice president and head of North America commercial. “We are proud to bring an additional offering to the physicians and patients seeking treatment options for OA knee pain.”
Teva's 1% sodium hyaluronate is supplied in a 3 mL disposable prefilled syringe containing 2 mL of 1% sodium hyaluronate, and packaged as three syringes to a carton.